Form 4: Glaukos Corp President & COO Joseph E. Gilliam Reports Stock Option Exercise and Sale
SEC Form 4 Filing
Joseph E. Gilliam, President & COO of Glaukos Corporation, exercised stock options and sold shares of common stock on October 30, 2024, according to a Form 4 filing with the SEC.
Summary
- On October 30, 2024, Joseph E. Gilliam, the President & COO of Glaukos Corporation, exercised stock options to acquire 2,275 shares of common stock at a price of $69.30 per share.
- Simultaneously, Gilliam sold 2,275 shares of Glaukos common stock at a weighted average price of $138.97 per share, with individual trades ranging from $138.60 to $139.47.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2024.
- Following these transactions, Gilliam directly owns 102,169 shares of Glaukos common stock, which includes 76,419 unvested restricted stock units and 324 shares purchased through the Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Executive stock transactions are common and are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are often used to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedule of the options is fairly standard, with 25% vesting after one year and the remainder vesting monthly over the following three years.
- The use of a 10b5-1 trading plan is a common practice among corporate executives to sell shares in a pre-planned manner.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| March 4, 2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| March 14, 2019 | Date the stock option was granted. |
| March 14, 2023 | Date the stock option vested in full. |
| October 30, 2024 | Date of the stock option exercise and sale of shares. |
| March 14, 2029 | Expiration date of the stock option. |
| November 01, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.